---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-220529"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:13:51.827482+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology appoints Michael Vasconcelles, M.D. to board and compensation committee

## Summary
- Appointed as Class III director with term expiring at 2026 annual meeting.
- Annual cash retainer $40,000 for board service plus $7,500 for Compensation Committee.
- Granted option to purchase 52,000 shares (3-year vest) and 17,333 shares (1-year cliff).
- Eligible for future automatic annual option grants of 26,000 shares.
- Standard indemnification agreement; no reportable transactions under Item 404.

## SEC filing metadata
- accession: 0001193125-24-220529
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312524220529/0001193125-24-220529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312524220529/d866748d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-220529
- JSON: https://secwatch.observer/filing/0001193125-24-220529.json
- Plain text: https://secwatch.observer/filing/0001193125-24-220529.txt

## Key facts
- Executive change
  Michael J. Vasconcelles, M.D. was appointed as Class III Director at Kura Oncology, Inc..
  - Action: appointed
  - Role: Class III Director
  source text: On September 13, 2024, the Board of Directors (the “Board”) of Kura Oncology, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Michael J. Vasconcelles, M.D. as (i) a Class III director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422143/000119312524220529/0001193125-24-220529-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.